Left ventricular mass and cardiovascular morbidity in essential hypertension: the MAVI study


		Search


	Submit Manuscripts
	Author Information
	Subscribe/Renew
	Order Reprints
	Email Alerts
	Feedback
	RSS Feed
	CME


	About the Journal
	Editorial Board & Staff


	About JACC CME
	Hardware/Software Requirements
	Contact Us
	Policy on Privacy and Confidentiality
	Copyright Information


Still not a subscriber to JACC Imaging or JACC Interventions? Click here to sign up now!


	ACC.org
	Cardiosmart
	Cardiosource
	CVN
	Imaging Library
	JACC Imaging
	JACC Interventions

2009 ACCF/AHA Focused Update on Perioperative Beta Blockade Incorporated Into the ACC/AHA 2007 Guidelines on Perioperative Cardiovascular Evaluation and Care for Noncardiac Surgery

ACC 2009 Advocacy Position Statement: Principles for Comparative Effectiveness Research

ACC 2009 Survey Results and Recommendations: Addressing the Cardiology Workforce Crisis

J Am Coll Cardiol, 2001; 38:1829-1835
© 2001 by the American College of Cardiology Foundation

This Article

	Abstract
	Full Text
	Full Text (PDF)
	Alert me when this article is cited
	Alert me if a correction is posted

Services

	Email this article to a friend
	Similar articles in this journal
	Similar articles in PubMed
	Alert me to new issues of the journal
	Download to citation manager

Citing Articles

	Citing Articles via HighWire
	Citing Articles via Google Scholar

Google Scholar

	Articles by Verdecchia, P.
	Search for Related Content

PubMed

	PubMed Citation
	Articles by Verdecchia, P.

Left ventricular mass and cardiovascular morbidity in essential hypertension: the MAVI study

Paolo Verdecchia, MD, FACC^*^,a, Giancarlo Carini, MD^a, Antonio Circo, MD^a, Emilio Dovellini, MD^a, Ezio Giovannini, MD^a, Michele Lombardo, MD^a, Pasquale Solinas, MD^a, Marco Gorini, MD^a, Aldo Pietro Maggioni, MD^a the MAVI Study Group

^a ANMCO Research Center, Via La Marmora, 36 Firenze, Italy. Please see for MAVI Study Group participants

View larger version (22K):

[in a new window]

Figure 1 Distribution of antihypertensive regimens at entry and on follow-up. ACE = angiotension-converting enzyme.

View larger version (18K):

[in a new window]

Figure 2 Cumulative incidence (left) and crude rate (right) of cardiovascular (CV) events in the subjects with and without left ventricular (LV) hypertrophy at echocardiography. BSA = body surface area.